Posts

Biopharma Bites: 白宮AI挑戰、Mentari新資金、Royalty Pharma與Neurimmune交易

on

Insilico and Bora Unveil AI-Driven Manufacturing and CDMO Platform Plans

on

Insilico lands heavily backloaded $2.5B AI drug discovery deal with SK Biopharm

on

Driven by GLP‑1s, Pharma’s Relationship with Consumers Is Starting to Change

on

Reframing What’s Possible in Pharma Commercialization (2026 Outlook)

on

Recent developments in transforming oversight and risk management in pharma R&D

on

Capricor Sues Nippon Shinyaku and NS Pharma Over Pricing Flaw and Launch Delays for Deramiocel DMD Therapy

on

GLP-1 Patent Cliffs and Biotech M&A Surge in 2026

on

Obesity Drugs Overtake Oncology as Top Driver of Pharma R&D Returns: Deloitte Report

on

Deloitte's 15th Annual Report: Pharma R&D Returns Rise to 5.9% in 2024 Driven by GLP-1 Therapies

on

Avalyn Pharma's Upsized $300M IPO Beats Expectations

on

Avalyn Pharma Stock Surges 44% After Upsized $300M IPO

on

Astellas Pharma Top Management Personnel Changes (October 2025)

on

Avalyn Pharma Aims for $182M IPO to Fund Phase 3 Trials of Inhaled Respiratory Drugs

on

Unnamed Pharma Files Citizen Petition Urging FDA to Reform CRL Disclosure Practices

on

OpenAI Debuts Life Sciences AI Model with Retro Biosciences Partnership

on

Revolution Medicines Secures $2B Funding from Royalty Pharma for RAS Cancer Drugs as Biotech Sector Heats Up

on

Spotlight On: Tackling Core Challenges in Drug R&D with AI

on

Astellas Pharma to Close Seattle Universal Cells Office with 50 Employee Layoffs

on

Avalyn Pharma Files for Nasdaq IPO to Advance Inhaled Pulmonary Fibrosis Treatments

on